?????? ????????????????????????? ?????????????? ?? ????.gene in patients relapsing after procedure Along with the BCL2 antagonist venetoclax. 66 Resistance to these brokers has become connected to these mutations in close to 70% of conditions, Even though they are often subclonal and their certain part creating resistance really should be demonstra